Document:

ex10h.htm

    EXHIBIT
10(h)

     

     

     

    MANAGEMENT
PERFORMANCE IMPROVEMENT PLAN

    (Amended and Restated as of
February 19, 2010)

    

    

    

    1.           Purpose.  The
purpose of the Plan, which provides for Performance Awards to be awarded to a
select group of management and highly compensated employees of the Company and
its Subsidiaries, is to promote the interests of the Company and its
Subsidiaries by linking financial incentives provided to such employees with
improvement in the Company's financial results.

    

    2.           Administration.  The
Plan will be administered by a Committee composed of at least three members of
the Company's Board of Directors each of whom shall qualify as (a) an
"outside director" within the meaning of Section 162(m) of the Code and
(b) a "nonemployee director" within the meaning of Rule 16b-3(b)(3)(i)
promulgated under the Securities Exchange Act of 1934, as
amended.  Until determined otherwise by the Board, the Compensation
and Benefits Committee designated by the Board shall be the Committee under this
Plan.

    

    Subject
to the express provisions of the Plan, the Committee shall have plenary
authority, in its discretion, to administer the Plan and to exercise all powers
and authority either specifically granted to it under the Plan or necessary and
advisable in the administration of the Plan, including without limitation the
authority to interpret the Plan; to prescribe, amend and rescind rules and
regulations relating to the Plan; to grant Performance Awards; to determine the
terms, provisions and conditions of all Performance Awards granted under the
Plan (which need not be identical), the individuals to whom and the time or
times when Awards shall be granted, and the performance measures used to
determine any payments of Performance Awards; and to make all other necessary or
advisable determinations with respect to the Plan.  The determination
of the Committee on such matters shall be conclusive.

    

    3.           Participation.  The
Committee may select from time to time key employees of the Company and its
Subsidiaries to participate in the Plan who, in the opinion of the Committee,
have the capacity to contribute significantly to the successful performance of
the Company and its Subsidiaries.  An employee who is selected to be a
Participant for one Performance Measurement Period shall not have any rights to
be included as a Participant for subsequent Performance Measurement
Periods.

    

    4.           Performance
Awards.  (a) Performance Awards may be, but are not
required to be, granted annually.  Each Performance Award shall
provide that a Participant will be entitled to a cash payment following the
completion of a designated Performance Measurement Period (which shall be three
fiscal years of the Company), subject to the satisfaction of conditions set
forth in the Plan, and the achievement of certain goals established by the
Committee in connection with each Performance Award.  Cash payments to
which a Participant may be entitled following the conclusion of each Performance
Measurement Period shall be determined based on the satisfaction of various
performance measures, as the Committee

    
      
         

      

      
         

        
          

        

      

      
        2

      

    

    shall
determine in the case of each Performance Award, including, but not limited to,
net income, operating income, return on net assets, revenue growth, total
shareholder return, earnings per share, return on equity, net revenue per
employee, market share, return on capital and/or economic value added (or
equivalent metric), and/or cash flow and/or free cash flow (before or after
dividends), with respect to the Company, any Subsidiary and/or business unit of
the Company or any Subsidiary; each as determined in accordance with generally
accepted accounting principles, where applicable, as consistently applied by the
Company and, if so determined by the Committee prior to the expiration of the
Performance Measurement Period, adjusted, to the extent permitted under Section
162(m) of the Code, to omit the effects of extraordinary items, the gain or loss
on the disposal of a business segment, unusual or infrequently occurring events
and transactions, accruals for awards under the Plan and cumulative effects of
changes in accounting principles.  Performance measures may vary from
Performance Measurement Period to Performance Measurement Period and from
Participant to Participant and may be established on a stand-alone basis, in
tandem or in the alternative.  Performance
measures may be expressed on an absolute basis or on a relative basis against a
peer group or an index.  The Committee shall determine and establish
in writing, with respect to each Performance Award, the performance measures for
each year of the Performance Measurement Period (including the levels of
performance measures that must be achieved to receive corresponding levels of
cash payments); provided, however, that minimum
performance measures for the full Performance Measurement Period (which
performance measures may be raised in subsequent years) shall be established in
writing no later than 90 days after the commencement of the Performance
Measurement Period.  Each Performance Award shall include a
(i) target level of performance measures which if satisfied will entitle a
Participant to 100% of a specified target dollar amount and (ii) maximum
payment (specified in dollars) which may not be greater than 200% of the target
dollar amount described in subparagraph (i).  The maximum incentive
payment any one Participant may be entitled to receive (whether or not deferred
as described in Section 4(c) below) for any one Performance Measurement
Period is $3,000,000.  Notwithstanding the foregoing, with respect to
Performance Measurement Periods beginning on or after January 1, 2005 and
provided that no Change of Control shall have occurred, the Committee may, in
its discretion, reduce any payment to which a Participant who is an employee of
the Company would otherwise be entitled by such amount or percentage as the
Committee deems appropriate.

    

    (b) A
Performance Award shall terminate for all purposes unless the Participant
remains continuously employed by the Company or a Subsidiary until the date
established by the Committee for payment of the Performance Award unless the
termination is (i) due to Retirement, Disability or death;
(ii) approved by the Committee; or (iii) subsequent to a Change in
Control.  In the event a Participant's employment is terminated due to
Retirement, Disability or death, he or she (or, in the event of the
Participant's death, his or her beneficiary) will be entitled to a prorated
portion of the Performance Award to which he or she would otherwise be entitled
based on the portion of the Performance Measurement Period (determined in
completed months) during which he or she was continuously employed by the
Company or a Subsidiary and based on the extent to which the performance goals
were achieved as determined at the end of the Performance Measurement
Period.  In the event of a Participant's termination of employment for
reasons other than Retirement, Disability or death, the Committee may, but is
not obligated to, 

    
      
         

      

      
         

        
          

        

      

      
        3

      

    

    authorize
payment of an amount up to the prorated amount that would be payable under the
preceding sentence.  In the event of a Change in Control, Performance
Awards shall be deemed to be earned at 100% of the specified target dollar
amount described in Section 4(a)(i) and shall be paid as soon as
practicable following the earlier of the Participant's termination of employment
after the Change in Control or the end of the Performance Measurement Period
during which the Change in Control occurred, but in no event later than March
15th immediately following the end of the first calendar year in which such
Change in Control occurred.

    

    (c)  Participants
entitled to receive a Performance Award for a Performance Measurement Period
will be entitled to receive a lump-sum cash payment on a date selected by the
Committee following the end of the Performance Measurement Period (which, for
Participants who are U.S. taxpayers, shall be no later than March 15th
immediately following the end of the first calendar year in which such
Performance Award was earned and vested) provided that the performance measures
are met.  Notwithstanding the preceding sentence, Participants may
elect to defer the receipt of payment of a Performance Award under the Key
Employees' Deferred Compensation Program of The Brink’s Company in accordance
with the terms of such plan.  Any payments made under this Plan shall
be subject to all applicable Federal, state or local taxes required by law to be
withheld.

    

    5.           Designation of
Beneficiary.  A Participant may designate, in a written
election filed with the Company, a beneficiary or beneficiaries (which may be an
entity other than a natural person) to receive all distributions and payments
under the Plan after the Participant's death.  Any such designation
may be revoked, and a new election may be made, at any time and from time to
time, by the Participant without the consent of any beneficiary (unless
otherwise required by law).  If the Participant designates more than
one beneficiary, any distributions and payments to such beneficiaries shall be
made in equal percentages unless the Participant has designated otherwise in
writing, in which case the distributions and payments shall be made in the
percentages designated by the Participant.  If no beneficiary has been
named by the Participant or no beneficiary survives the Participant, any amounts
due to the Participant shall be distributed or paid in a single sum to the
Participant's estate.

    

    6.           Nonexclusive
Plan.  The adoption of the Plan shall not be construed as
creating any limitations on the power of the Company to adopt such other
incentive arrangements as it may deem desirable and such arrangements may be
either generally applicable or applicable only in specific cases.

    

    7.           Nonassignability.  No
Performance Awards may be transferred, alienated or assigned other than by will
or by the laws of descent and distribution.

    

    8.           Amendment and
Termination.  The Board of Directors may amend or terminate
this Plan at any time without the approval of the Company's
shareholders.

    

    9.           Effectiveness of the
Plan.  The Plan shall become effective on January 1, 2000,
provided that the Plan is approved by the Company’s shareholders at the annual
meeting of shareholders occurring in calendar year 2000.

    
      
         

      

      
         

        
          

        

      

      
        4

      

    

    10.           No Right to Continued
Employment.  Neither the adoption of the Plan nor any action of
the Board or Committee shall be deemed to give any officer or employee any right
to continued employment or any other rights other than to payments under a
Performance Award granted hereunder in accordance with the terms of such
award.

    

    11.           Governing
Law.  The Plan shall be construed and interpreted under the
laws of the state of New York.

    

    12.           Definitions.  For
the purpose of this Plan, unless the context requires otherwise, the following
terms shall have the meanings indicated:

    

    (a)  "Board of Directors"
means the board of directors of the Company.

    

    (b)  "Cause" means, with
respect to any Participant, (i) embezzlement, theft or misappropriation by the
Participant of any property of the Company, (ii) the Participant’s willful
breach of any fiduciary duty to the Company, (iii) the Participant’s willful
failure or refusal to comply with laws or regulations applicable to the Company
and its business or the policies of the Company governing the conduct of its
employees, (iv) the Participant’s gross incompetence in the performance of the
Participant’s job duties, (v) commission by the Participant of a felony or of
any crime involving moral turpitude, fraud or misrepresentation, (vi) the
failure of the Participant to perform duties consistent with a commercially
reasonable standard of care or (vii) any gross negligence or willful misconduct
of the Participant resulting in a loss to the Company.

    

    (c)  "Change in Control"
shall have the meaning ascribed to such term under The Brink’s Company 2005
Equity Incentive Plan, as amended from time to time, or any successor to such
plan, provided, however,
that references to “Awards” therein shall be deemed to be references to
“Performance Awards” herein.

    

    (d)  "Code" means the
Internal Revenue Code of 1986, as amended.

    

    (e)  "Committee" means the
Compensation and Benefits Committee of the Company or any successor thereto
unless determined otherwise by the Board of Directors.

    

    (f)  "Company" means The
Brink’s Company, a Virginia corporation.

    

    (g)  "Disability" means a
physical or mental incapacity which would entitle the Participant to benefits
under the Company's long-term disability plan.

    

    (h)  "Participant" means an
employee who has been selected by the Committee to participate in the
Plan.

    

    (i)  "Performance Award"
means an incentive award made pursuant to the Plan.

    
      
         

      

      
         

        
          

        

      

      
        5

      

    

    (j)  "Performance Measurement
Period" means a performance cycle of one or more fiscal years of the
Company.  The initial Performance Measurement Period shall be
2000-2002 (inclusive).

    

    (k)  "Plan" means The
Brink’s Company Management Performance Improvement Plan as amended from time to
time.

    

    (l)  "Retirement" means,
with respect to any Participant, any termination of the Participant’s employment
on or after the date on which the Participant has (i) attained age 65 and
completed at least five years of service with the Company or any of its
Subsidiaries or (ii) attained age 55 and completed at least ten years of service
with the Company or any of its Subsidiaries; provided that the
Participant’s employment is not terminated for Cause.

    

    (m)  "Subsidiary" means any
corporation more than 80% of the outstanding voting stock of which is owned by
the Company, by the Company and one or more Subsidiaries or by one or more
Subsidiaries.   "Subsidiaries" means more than one of any such
corporation.exhibit1013.htm

Exhibit 10.13

 

GLOBAL HEADQUARTERS

101 Gordon Drive ∙ Lionville, PA  19341

TEL 610-594-3327 ∙ FAX 610-594-3013

rick.luzzi@westpharma.com

RICHARD D. LUZZI

Vice President, Human Resources

December 22, 2009

Mr. Matthew T. Mullarkey

29844 Lake Road

Bay Village, OH 44140

Re:           Severance Benefits

Dear Matt:

As discussed, you and West Pharmaceutical Services, Inc. (the “Company”) have mutually agreed to end your employment effective November 18, 2009 (the “Termination Date”).  This letter agreement contains the terms of certain benefits the Company is willing to provide you and other arrangements and agreements
in connection with your termination of employment.  In recognition of your service to the Company and as additional consideration for your execution of the Release attached to this letter agreement as Exhibit A, the Company and you agree as follows:

 

	
1.  
	
Termination of Employment. Effective
as of the Termination Date, your employment with the Company is terminated.  As of the Termination Date, you confirm your termination from all offices, positions, trusteeships, committee memberships and fiduciary capacities held with, or on behalf of, the Company.  As of the Termination Date, you will not represent yourself as being an employee, officer, trustee, agent or representative of any of the foregoing for any purpose.  You acknowledge and agree that the Company will not
have an obligation to rehire you or to consider you for reemployment after the Termination Date.

 

	
2.  
	
Severance and Non-Competition Agreement. Your termination of employment is a termination other than for cause or by reason of death, disability or retirement, which entitles
you to the benefits payable on termination described in Section 2 of your Severance and Non-competition Agreement, dated July 28, 2008 and attached to this letter agreement as Exhibit B, provided that you satisfy all of the conditions and obligations contained in that agreement, including the requirements to execute a release, and abide by the terms of your Confidentiality Agreement, attached as Exhibit
C  and the covenant not to compete contained in Section 4 of the Severance and Non-Competition Agreement.

  

  

  

 

	
3.  
	
Additional Benefits Payable Upon Termination of Employment.  In
addition to the benefits provided upon termination of employment as described in your Severance and Non-competition Agreement, the Company will provide the following:

 

	
a)  
	
2009 Annual Bonus.  You will be eligible to receive a payout of the bonus that you would otherwise be entitled to receive (if any) under the terms of the Company’s Management Incentive Plan with respect to the 2009 fiscal year had you remained employed through the
bonus payment date.  The annual bonus will be paid in cash only and will be paid at the same time as it is paid to other executive officers of the Company and will be subject to the same conditions and restrictions applicable to the payments to the other executive officers.

 

	
    b)
	
Residential Lease Termination.  We will reimburse you for any reasonable direct costs associated with the early termination of the lease for the residence that you maintain in the West Chester, Pennsylvania area.  To be eligible for reimbursement, such costs
must be separately itemized, documented in writing and submitted to the Company.

 

	
c)  
	
Relocation of Goods.  We will reimburse you for the reasonable direct costs of relocating your personal and household effects from your West Chester, Pennsylvania residence to a location in the contiguous United States that you specify in writing within 180 days following
your termination date.  To be eligible for reimbursement, such costs must be separately itemized, documented in writing and submitted to the Company.

 

	
d)  
	
Stock Options.  The stock options granted to you by the Company on July 28, 2008 and February 24, 2009 will continue to vest according to their terms through February 28, 2010 and all vested options shall remain exercisable through 12:01 AM on November 18, 2010, at which
time they will expire and will no longer be exercisable.  Except as modified by this letter agreement, there are no additional modifications to your outstanding stock options.

 

	
e)  
	
Certain Performance-Vesting Share Units.  The Performance Vesting Share Units granted to you on July 28, 2009 with respect to Performance Period VI (2007-2009) only shall be payable to you to the extent and in the same manner and at the same time as awards for that performance
period are paid to other executive plan participants.  All other Performance Vesting Share Units granted to you have been forfeited as of your Termination Date.

 

	
f)  
	
Outplacement Assistance.  Through November 17, 2010, you shall be given access to outplacement services at our cost from a provider selected solely at our discretion and provided at a time and place to be determined in our sole discretion.

  

  

  

 

	
4.  
	
Payments Final and Exclusive. The arrangements provided for by this letter agreement, or any other agreement between the Company and you in effect at that time and by any other
applicable plan of the Company in which you participate constitute the entire obligation of the Company to you, and performance of that obligation constitutes the settlement of any claim that you might otherwise assert against the Company on account of your termination.  You will not separately be entitled to any severance under any applicable plan, agreement or policy of the Company, and you will not be entitled to receive any of the benefits under your Change in Control Agreement with the Company,
dated July 28, 2008.

 

	
5.  
	
Enforcement. You acknowledge that a breach of this letter agreement, including any exhibit to this letter agreement, will cause the Company immediate and irreparable harm for
which the Company’s remedies at law (such as money damages) will be inadequate. The Company will have the right, in addition to any other rights it may have, to obtain an injunction to restrain any breach or threatened breach of this letter agreement. If any provision of this letter agreement be adjudged to any extent invalid by any competent tribunal, that provision will be deemed modified to the extent necessary to make it enforceable.

 

	
6.  
	
Application of Code Section 409A. Notwithstanding anything in this letter agreement to the contrary, to the extent that any payments or benefits provided by this letter agreement, pursuant to your Severance and
Non-Competition Agreement or otherwise, cannot be paid before the date that is six months following your Termination Date without application of the 20% additional tax imposed by section 409A of the Internal Revenue Code of 1986, such payments shall be delayed until the first normal payroll date on or following May 18, 2010.  The payment on such payroll date shall include a lump sum equal to any delayed payments plus any normal severance payments to which you are otherwise entitled on that date.

 

	
7.  
	
Miscellaneous.

 

	
a)  
	
This letter agreement will be binding upon and inure to your benefit, your personal representatives and heirs and the Company and any successor of the Company, but neither this letter agreement nor any rights or obligations arising under it may be assigned or pledged by you.

 

	
b)  
	
The laws of the Commonwealth of Pennsylvania (without giving effect to it conflicts of law principles) govern all matters arising out of or relating to this letter agreement, including its validity, interpretation, construction, performance and enforcement.  No action involving this letter agreement may be brought except in the state courts located
in Chester County, Pennsylvania or the Federal District Court for the Eastern District of Pennsylvania.

 

	
c)  
	
This letter agreement constitutes the entire agreement and understanding between the Company and you with respect to this letter agreement and supersedes all other oral or written agreements or policies relating to the matter of this letter agreement.

 

  

  

  

	
d)  
	
The parties may execute this letter agreement in any number of duplicate originals, each of which constitutes an original and all of which collectively constitute only one agreement.

 

If this letter agreement correctly reflects the terms agreed by the Company and you, please sign a copy of this agreement in the space provided below and return it by overnight courier to the address of the Company stated above, to the attention of Richard D. Luzzi.

 

 

Very truly yours,

 

    WEST PHARMACEUTICAL SERVICES, INC.

    By:   

                        Richard
D. Luzzi

                                                                                                                    Vice
President, Human Resources

Agreed To as of ______________, 2009:

 

________________________

Matthew T. Mullarkey

  

  

  

EXHIBIT A

RELEASE

 

	
NOTICE:  This is a very important legal document, and you should thoroughly review and understand the terms and effect of this document before signing it.  By signing this Release, you will be completely releasing West Pharmaceutical Services, Inc. and its affiliates from all liability
to you.  Therefore, you should consult with an attorney before signing this Release.  You have twenty-one (21) days from the date of distribution of these materials to consider this document.  If you have not returned a signed copy of this Release by that time, we will assume that you have elected not to sign the Release.  If you choose to sign the Release, you will have an additional
seven (7) days following the date of your signature to revoke the Release, and the Release between you and the Company shall become effective or enforceable until the revocation period has expired.  Any revocation of this Release must be in writing and must be personally delivered or mailed to Richard D. Luzzi, Vice President, Human Resources.

Intending to be legally bound by the provisions of the attached letter agreement and in consideration of the negotiated payments and benefits specified in the letter agreement to which this Release is attached as Exhibit A, which shall be incorporated as if fully set forth within, dated December 10, 2009, between West Pharmaceutical Services,
Inc. and me, providing valuable consideration to which I would otherwise not be entitled, I, Matthew T. Mullarkey, hereby, fully, forever, unconditionally, and, except as specifically provided herein, irrevocably release and discharge West Pharmaceutical Services, Inc. and its affiliates, parents, subsidiaries, successors, and predecessors and all of their employees, agents, attorneys, officers, and directors (individually and collectively referred to as the “Company”) from any and all claims, charges,
complaints, demands, causes of action, suits, rights, debts, costs, covenants, contracts, agreements, acts or omissions, damages, obligations, liabilities, and expenses (including attorneys' fees and costs) of every kind and nature which I ever had or now have, whether or not such Claims are known to me or the Company or unknown, against the Company arising out of my employment with or separation from the Company (collectively, the “Claims”).

 

For avoidance of confusion, Claims arising out of any of the following are released: (1) Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., (2) the Age Discrimination in Employment Act (“ADEA”), 29 U.S.C., § 621 et seq. as amended; (3) The Older Worker Benefit Protection Act of 1990, 29 U.S.C. §
623 (“OWBPA”), as amended; (4) The Americans With Disabilities Act of 1990 (“ADA”), 42 U.S.C., §12101 et seq., as amended; (5) The Rehabilitation Act of 1973, 29 U.S.C. § 2101, et seq., (6) the Family and Medical Leave Act of 1993 (“FMLA”), 29 U.S.C. § 2601, et seq., as amended; (7) The Fair Credit Reporting Act (“FCRA”), 15 U.S.C. § 1681 et seq., as amended; (8) The Employee Retirement Income Security Act of 1974 ("ERISA"), 29 U.S.C. §
1001 et seq., as amended, (9) the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., as amended; (10) the Equal Pay Act of 1963, 29 U.S.C. § 602 et seq., as amended; (11) the Lilly Ledbetter Fair Pay Act of 2009, as amended; (12) the Fair Labor Standards Act of 1938. 29 U.S.C. § 201 et seq., as amended,  and (13) all other applicable state, or local governances or ordinances governing employment or termination of employment, including: the
Pennsylvania Human Relations Act, the Pennsylvania Wage Payment and Collection Law, as amended; The Pennsylvania Minimum Wage Act, as amended;  The Pennsylvania Equal Pay Law,  as amended; and (14) all common law claims including, but not limited to, actions in tort, defamation and breach of contract, including, without limitation, claims for severance benefits.

 

Additionally, except as specifically provided in the next paragraph, I release the Company from all claims to any ownership interest in the Company; any claims that I may have that are related to a right I may have now or in the future as a result of a change in ownership control of the Company; any other claims or damages arising out of
my employment with or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local ordinance not expressly referenced above any and all claims and/or causes of action, whether known to you or the Company at the time of the execution of this Release or not, which I may have or could claim to have against the Company in connection with my employment with the Company or termination of employment
with the Company up to and including the date of my signing of this Release.

 

 

 

 

Notwithstanding anything herein to the contrary, I am not releasing or waiving any of my rights pursuant to this Release that relate to (i) any retirement plans sponsored by the Company, (ii) stock options and performance vesting shares awarded under the 2007 Omnibus Incentive Compensation Plan to the extent modified by the attached letter
agreement, and (iii) any rights or promises made to me by the letter agreement.

 

By signing below, I acknowledge that I have carefully read and fully understand the provisions of this Release.  I further acknowledge that I am signing this Release knowingly and voluntarily and without duress, coercion or undue influence.  I agree that I will not file a lawsuit asserting any claims barred by this Release
against the Company.  If I breach this promise, then I will reimburse the Company for its reasonable attorneys’ fees and costs incurred in defending against such released Claims, and I shall also be obligated to tender back upon filing of such complaint in state or federal court or before any administrative agency any consideration that I have received pursuant to the severance arrangements provided within the accompanying letter agreement.  A suit challenging the validity of this Release
under ADEA, however, shall not be subject to the provisions of this paragraph.

 

I agree that this Release may be pleaded as a complete bar to any action or suit before any court, arbitral or administrative body with respect to any of the released claims.

 

This Release together with the letter agreement constitutes the total and complete understanding between me and the Company relating to the subject matter covered by this Release and all other prior or contemporaneous written oral agreements or representations, except the accompanying agreement setting forth the terms of my severance arrangement,
if any, otherwise relating to the subject matter of this Release are null and void.  It is also expressly understood and agreed that the terms of this Release may not be altered except in writing signed by both the Company and me.  I further understand and agree that the terms and conditions of this Release shall not be communicated to any persons other than those referred to herein and to my spouse or legal counsel, if applicable.  Finally, it is understood and agreed that the execution
of this Release is not an admission of liability on the part of either party.

 

The laws of the Commonwealth of Pennsylvania (without giving effect to it conflicts of law principles) govern all matters arising out of or relating to this Release, including its validity, interpretation, construction, performance and enforcement.  No action involving this Release may be brought except in the state courts located
in Chester County, Pennsylvania or the Federal District Court for the Eastern District of Pennsylvania.

If any provision of this Release, or the application thereof, is held to be invalid, void or unenforceable for whatever reason, the remaining provisions not so declared shall nevertheless continue in full force and effect without being impaired in any manner whatsoever.   If any party waives any provision of this Agreement,
such waiver shall not affect any provision of the agreement not specifically waived.

INTENDING TO BE LEGALLY BOUND, I have executed and dated this Release below

 

____________________________

Matthew T. Mullarkey

DATED:

_____________________________

  

  

  

EXHIBIT B

SEVERANCE AND NONCOMPETE AGREEMENT

 

  

  

  

EXHIBIT C

CONFIDENTIALITY AGREEMENT

  

  

  

EXHIBIT A

Confidentiality Agreement With

West Pharmaceutical Services, Inc. and Subsidiaries

_________________________________________

In consideration of my employment by West Pharmaceutical Services, Incorporated, The Tech Group or any of each of their subsidiaries or affiliates (the “Company”), and intending to be legally bound, I, Matthew T. Mullarkey, agree as follows:

1. INVENTIONS COMPANY PROPERTY.  In this Agreement the term “Inventions” includes inventions, ideas, techniques, methods, developments, improvements and all other forms of intellectual
property.  All rights in Inventions which I conceive, make or obtain either alone or with others during my employment by the Company (both before and after the date of this Agreement) and within six months after my employment ends, are and shall be the property of the Company except as set forth in Section 2 of this Agreement.

2.  INVENTIONS EXCLUDED.  This Agreement does not apply to Inventions which the Company determines in its sole discretion to be unrelated to any matter of actual or potential interest to the Company unless they are conceived, made or obtained
in the course of my employment or with the use of the time, material or facilities of the Company.  This agreement also does not apply to Inventions conceived, made or obtained by me before my employment by the Company.  As a matter of record, I include at the end of this Agreement a list of such prior Inventions.

3. DISCLOSURE AND PROTECTION OF INVENTIONS.  I will make full and prompt disclosure to the Company of all Inventions which are defined by Section 1 to be the Company’s property.  At
the Company’s request and expense but without additional compensation to me, I will at any time take such actions as the Company reasonably considers necessary to obtain or preserve the Company’s rights in such Inventions.  These actions may include, but are not necessarily limited to, signing and delivering applications, assignments and other papers and testifying in legal proceedings.

4.  CONFIDENTIAL INFORMATION.  I will not, during or after my employment with the Company, use for myself or others, or disclose to others, any formulae, trade secrets, know-how, Inventions which are the Company’s property, data provided
to the Company by clients, customers, or licensors, including Inventions owned by Third Parties (as defined below), or other confidential matters of the Company or its affiliates unless authorized in writing to do so by the Company.  I understand that (a) the Company keeps these matters confidential and secret, (b) these confidential matters would be of great value to competitors, and (c) if these confidential matters were known to the Company’s competitor’s, the Company would be harmed.  As
used in this agreement, “confidential matters of the Company” includes all information of a technical, commercial or other nature and any other information not made available to the general public, including, but not limited to information covered by a confidentiality agreement.

5.  THIRD PARTIES. You understand that, in dealing with existing and potential customers, clients, licensees, licensors, suppliers, contracting parties and other third parties with which the Company has business relations or potential business relations
(“Third Parties”), the Company frequently receives confidential and proprietary information and materials from these Third Parties subject to the Company's understanding that the Company will maintain the confidentiality of such information and the Company requires its employees and consultants to do so.  You agree to treat all such information and materials as confidential information subject to this Agreement.

  

  

  

6.  PAPERS.  All correspondence, memoranda, notes, records, reports, drawings, lists, photographs, plans and other papers and items received or made by me in connection with my employment with the Company shall be the property of the Company.  I
will deliver all copies of such materials to the Company upon request of the Company and, even if it does not request, when my employment by the Company ends.

7.  ENFORCEMENT.   I acknowledge that a breach of this agreement will cause the Company immediate and irreparable harm for which the Company’s remedies at law (such as money damages) will be inadequate.  The Company
shall have the right, in addition to any other rights it may have, to obtain an injunction to restrain any breach or threatened breach of this Agreement.  Should any provision of this agreement be adjudged to any extent invalid by any competent tribunal, that provision would be deemed modified to the extent necessary to make it enforceable.   The Company may contact any person with or for whom I work after my employment by the Company ends and may send that person a copy of this agreement.  If
suit is brought to enforce this Agreement, the party which substantially prevails on the merits is entitled to recover as an element of costs of suit, and not as damages, reasonable attorneys' fees and expenses and all expert witnesses' fees and expenses incurred by the prevailing party.

8.  BINDING EFFECT; SEVERABILITY.  My undertakings hereunder will bind me and my heirs and legal representatives regardless of (a) the duration of my employment by the Company, (b) any change in my duties or the nature of my employment,
(c) the reasons for manner of termination of my employment, and (d) the amount of my compensation.  The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision hereof.

9.  MISCELLANEOUS.  This agreement (a) shall in no way bind me or the Company to a specific term of employment, (b) supersede any prior understandings and constitutes the entire understanding between the Company and me about the subject
matter covered by this agreement, (c) may be modified or varied only in writing signed by the Company and me, (d) will inure to the benefit of the successors and assigns of the Company, and (e) will be governed by Pennsylvania law.

MATTHEW T. MULLARKEY

________________________________________________

Dated:     _________________________________________

List below or on a separate page all previous Inventions referred to in Section 3 above (if none please so indicate).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}]]